Inhibitory effects of 190 compounds against SARS-CoV-2 Mpr o protein : Molecular docking interactions
© 2023 Deutsche Pharmazeutische Gesellschaft..
COVID-19 has caused many deaths since the first outbreak in 2019. The burden on healthcare systems around the world has been reduced by the success of vaccines. However, population adherence and the occurrence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants are still challenging tasks to be affronted. In addition, the newly approved drug presents some limitations in terms of side effects and drug interference, highlighting the importance of searching for new antiviral agents against SARS-CoV-2. The SARS-CoV-2 main protease (Mpr o ) represents a versatile target to search for new drug candidates due to its essential role in proteolytic activities responsible for the virus replication. In this work, a series of 190 compounds, composed of 27 natural ones and 163 synthetic compounds, were screened in vitro for their inhibitory effects against SARS-CoV-2 Mpro . Twenty-five compounds inhibited Mpro with inhibitory constant values (Ki ) between 23.2 and 241 µM. Among them, a thiosemicarbazone derivative was the most active compound. Molecular docking studies using Protein Data Bank ID 5RG1, 5RG2, and 5RG3 crystal structures of Mpro revealed important interactions identified as hydrophobic, hydrogen bonding and steric interactions with amino acid residues in the active site cavity. Overall, our findings indicate the described thiosemicarbazones as good candidates to be further explored to develop antiviral leads against SARS-CoV-2. Moreover, the studies showed the importance of careful evaluation of test results to detect and exclude false-positive findings.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:356 |
|---|---|
| Enthalten in: |
Archiv der Pharmazie - 356(2023), 8 vom: 03. Aug., Seite e2300207 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Souza, Gabriella B [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antiviral Agents |
|---|
| Anmerkungen: |
Date Completed 08.08.2023 Date Revised 08.08.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1002/ardp.202300207 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM357575490 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM357575490 | ||
| 003 | DE-627 | ||
| 005 | 20231226072904.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1002/ardp.202300207 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1191.xml |
| 035 | |a (DE-627)NLM357575490 | ||
| 035 | |a (NLM)37255416 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Souza, Gabriella B |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Inhibitory effects of 190 compounds against SARS-CoV-2 Mpr o protein |b Molecular docking interactions |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 08.08.2023 | ||
| 500 | |a Date Revised 08.08.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023 Deutsche Pharmazeutische Gesellschaft. | ||
| 520 | |a COVID-19 has caused many deaths since the first outbreak in 2019. The burden on healthcare systems around the world has been reduced by the success of vaccines. However, population adherence and the occurrence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants are still challenging tasks to be affronted. In addition, the newly approved drug presents some limitations in terms of side effects and drug interference, highlighting the importance of searching for new antiviral agents against SARS-CoV-2. The SARS-CoV-2 main protease (Mpr o ) represents a versatile target to search for new drug candidates due to its essential role in proteolytic activities responsible for the virus replication. In this work, a series of 190 compounds, composed of 27 natural ones and 163 synthetic compounds, were screened in vitro for their inhibitory effects against SARS-CoV-2 Mpro . Twenty-five compounds inhibited Mpro with inhibitory constant values (Ki ) between 23.2 and 241 µM. Among them, a thiosemicarbazone derivative was the most active compound. Molecular docking studies using Protein Data Bank ID 5RG1, 5RG2, and 5RG3 crystal structures of Mpro revealed important interactions identified as hydrophobic, hydrogen bonding and steric interactions with amino acid residues in the active site cavity. Overall, our findings indicate the described thiosemicarbazones as good candidates to be further explored to develop antiviral leads against SARS-CoV-2. Moreover, the studies showed the importance of careful evaluation of test results to detect and exclude false-positive findings | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a SARS-CoV-2 Mpro | |
| 650 | 4 | |a enzyme assays | |
| 650 | 4 | |a molecular docking | |
| 650 | 4 | |a natural products | |
| 650 | 4 | |a thiosemicarbazones | |
| 650 | 7 | |a Protease Inhibitors |2 NLM | |
| 650 | 7 | |a Antiviral Agents |2 NLM | |
| 700 | 1 | |a Sens, Larissa |e verfasserin |4 aut | |
| 700 | 1 | |a Hammerschmidt, Stefan J |e verfasserin |4 aut | |
| 700 | 1 | |a de Sousa, Natália F |e verfasserin |4 aut | |
| 700 | 1 | |a de Carvalho, Maryelle A G |e verfasserin |4 aut | |
| 700 | 1 | |a Dos Santos, Carlos V D |e verfasserin |4 aut | |
| 700 | 1 | |a Tizziani, Tiago |e verfasserin |4 aut | |
| 700 | 1 | |a Moreira, Monalisa A |e verfasserin |4 aut | |
| 700 | 1 | |a Pollo, Luiz A E |e verfasserin |4 aut | |
| 700 | 1 | |a Martin, Erlon F |e verfasserin |4 aut | |
| 700 | 1 | |a Neto, José S S |e verfasserin |4 aut | |
| 700 | 1 | |a Biavatti, Maique W |e verfasserin |4 aut | |
| 700 | 1 | |a de Assis, Francisco F |e verfasserin |4 aut | |
| 700 | 1 | |a Ngadjui, Bonaventure T |e verfasserin |4 aut | |
| 700 | 1 | |a Simo, Ingrid K |e verfasserin |4 aut | |
| 700 | 1 | |a Ambassa, Pantaléon |e verfasserin |4 aut | |
| 700 | 1 | |a Scotti, Marcus T |e verfasserin |4 aut | |
| 700 | 1 | |a Scotti, Luciana |e verfasserin |4 aut | |
| 700 | 1 | |a Braga, Antonio L |e verfasserin |4 aut | |
| 700 | 1 | |a Schirmeister, Tanja |e verfasserin |4 aut | |
| 700 | 1 | |a Sandjo, Louis P |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Archiv der Pharmazie |d 1972 |g 356(2023), 8 vom: 03. Aug., Seite e2300207 |w (DE-627)NLM000013323 |x 1521-4184 |7 nnns |
| 773 | 1 | 8 | |g volume:356 |g year:2023 |g number:8 |g day:03 |g month:08 |g pages:e2300207 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1002/ardp.202300207 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 356 |j 2023 |e 8 |b 03 |c 08 |h e2300207 | ||